Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Timothée Klopfenstein and N'dri Kadiane-Oussou.
Timothée Klopfenstein
Connection Strength
1.879
N'dri Kadiane-Oussou
  1. Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials. Rev Med Virol. 2022 01; 32(1):e2239.
    View in: PubMed
    Score: 0.235
  2. Is There Still a Place for Tocilizumab in Coronavirus Disease 2019? Open Forum Infect Dis. 2021 Feb; 8(2):ofab013.
    View in: PubMed
    Score: 0.231
  3. Angioedema and COVID-19: A New Dermatological Manifestation? Infect Dis Rep. 2021 Jan 01; 13(1):23-25.
    View in: PubMed
    Score: 0.230
  4. Comparison of COVID-19 and influenza in adult patients: Neurological symptoms input. J Med Virol. 2021 04; 93(4):1893-1895.
    View in: PubMed
    Score: 0.230
  5. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis. 2020 Oct; 99:491-495.
    View in: PubMed
    Score: 0.224
  6. New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France. Int J Infect Dis. 2020 Nov; 100:117-122.
    View in: PubMed
    Score: 0.224
  7. Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster. Microbes Infect. 2020 10; 22(9):481-488.
    View in: PubMed
    Score: 0.222
  8. Diarrhea: An underestimated symptom in Coronavirus disease 2019. Clin Res Hepatol Gastroenterol. 2020 06; 44(3):282-283.
    View in: PubMed
    Score: 0.220
  9. It Is Time to Determine Tocilizumab's Place in Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2022 02 11; 74(3):560-562.
    View in: PubMed
    Score: 0.062
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.